Drug Profile

Ocrelizumab biosimilar - CinnaGen

Alternative Names: Xacrel

Latest Information Update: 26 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CinnaGen
Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Urologics
Mechanism of Action Antibody-dependent cell cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Registered Multiple sclerosis

Most Recent Events

26 Jul 2022 Ocrelizumab biosimilar is still in phase III trials for Multiple sclerosis in Iran (IV) (NCT04966338)
31 Dec 2021 Registered for Multiple sclerosis in Iran (IV) on or before December 2021
19 Jul 2021 Cinnagen completes enrolment in its phase III trial for Multiple Sclerosis in Iran (NCT04966338)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com